New Release: Alpha testing version has been released.

Baclofen

M03B - Muscle relaxants, centrally acting agents ATC M03BX01 Small molecule approved 1977 Oral Parenteral Natural product Black-box warning

JFDA label: Lioresal Tab

⚠ Black-Box Warning
  • Abrupt withdrawal (injection):

Mechanism of Action

Agonist of GABA-B receptor — GABA-B receptor agonist

TargetActionGene / class
GABA-B receptor efficacy AGONIST

Indications

Approved

  • Intrathecal
  • Oral
  • Spasticity

Off-label

  • Alcoholic liver disease (alcohol abstinence)
  • Gastroesophageal reflux disease (adults)
  • Hiccups (singultus)
  • Nystagmus
  • Spasticity in cerebral palsy (children/adolescents) (short-term treatment)
  • Trigeminal neuralgia

Contraindications

Source: Lexicomp

  • Hypersensitivity to baclofen or any component of the formulation Intrathecal: IV, IM, SubQ, or epidural administration Absolute

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Cardiac disorders (2)

Common Hypotension · peripheral edema

Nervous system disorders (16)

Very Common confusion · drowsiness · headache · Hypotonia

Common abnormality in thinking · agitation · chills · coma · depression · dizziness · hypertonia · insomnia · pain · paresthesia · Seizure · speech disturbance

Renal and urinary disorders (5)

Common difficulty in micturition · impotence · urinary frequency · urinary incontinence · Urinary retention

Gastrointestinal disorders (6)

Very Common Nausea · vomiting

Common Constipation · diarrhea · sialorrhea · xerostomia

Skin and subcutaneous tissue disorders (2)

Common Pruritus · urticaria

Musculoskeletal and connective tissue disorders (3)

Common Back pain · tremor · weakness

Eye disorders (1)

Common Ambylopia

General disorders and administration site conditions (1)

Common Accidental injury

Respiratory, thoracic and mediastinal disorders (3)

Common dyspnea · Hypoventilation · pneumonia

Dosing

Source: Lexicomp

Spasticity: Oral: Initial: 5 mg 3 times daily; may increase by 5 mg per dose every 3 days (ie, 5 mg 3 times daily for 3 days, then 10 mg 3 times daily for 3 days, etc.) until optimal response is reached. Usual dosage range: 40 to 80 mg daily. Do not exceed 80 mg daily (20 mg 4 times daily). Intrathecal: Screening dose: Initial: 50 mcg for 1 dose; following initial administration, observe patient for 4 to 8 hours. A positive response consists of a significant decrease in muscle tone and/or frequency and/or severity of spasms. If response is inadequate, may give 75 mcg as a second screening dose 24 hours after the first screening dose; observe patient for 4 to 8 hours. If response is still inadequate, may repeat a final screening dose of 100 mcg given 24 hours after the second screening dose. Patients not responding to screening dose of 100 mcg should not be considered for chronic infusion/implanted pump. Dose titration following pump implant: After positive response to screening dose, a maintenance intrathecal infusion can be administered via an implanted intrathecal pump. Initial total daily dose via pump: Double the screening dose that gave a positive response and administer over 24 hours, unless efficacy of the bolus dose was maintained for >8 hours, then infuse a dose equivalent to the screening dose over 24 hours. Do not increase dose in first 24 hours (to allow steady state to be achieved); thereafter, dosage adjustments may be made by increasing daily dose slowly by 10% to 30% (spasticity of spinal cord origin) or 5% to 15% (spasticity of cerebral origin) once every 24 hours until satisfactory response. Maintenance: Daily dose may be increased 5% to 20% (maximum increase: 20%) (spasticity of cerebral origin) or by 10% to 40% (maximum increase: 40%) (spasticity of spinal cord origin). Dose may also be decreased 10% to 20% for adverse effects. Most patients have been adequately maintained on 90 mcg to 703 mcg daily (spasticity of cerebral origin) or 300 mcg to 800 mcg daily (spasticity of spinal cord origin). Experience with doses >1,000 mcg daily is limited. Note: Dosage adjustments may be required often during the first few months of therapy to adjust for life style changes due to alleviation of spasticity. Maintain lowest dose that produces adequate response. Most patients require gradual increases over time to maintain optimal response. Sudden large requirements for a dose increase may indicate a catheter complication (eg, kink, dislodgement).Titrate dose to allow sufficient muscle tone and occasional spasms to optimize activities of daily living, support circulation, and possibly prevent DVT formation. Use extreme caution when filling the pump; follow manufacturer instructions carefully. 5% to 10% of patients receiving chronic therapy become refractory to dose adjustments; may consider a drug holiday (hospitalized patients only) with a gradual withdrawal over 2 to 4 weeks and use of alternative spasticity management methods. Following th
(For additional information see "Baclofen: Pediatric drug information") Oral: Note: Use the lowest effective dose; patients who fail to respond within a reasonable amount of time should be slowly withdrawn from therapy (avoid abrupt withdrawal of drug). Spasticity: Oral: Children ≥12 years and Adolescents: Refer to adult dosing. Infants, Children, and Adolescents (off-label): Note: Dose-related side effects (eg, sedation) may be minimized by slow titration; lower initial doses than described below (2.5 to 10 mg daily) may be used with subsequent titration to 8 hourly doses. There is limited published data in infants and children; the following is a compilation of small prospective studies (Milla 1977; Scheinberg 2006) and one large retrospective analysis of baclofen use in children (Lubsch 2006). Efficacy results variable (AAN [Delgado] 2010) Infants ≥4 months and Children daily divided every 8 hours; begin at low end of range and titrate dose to patient response, titration intervals of every 3 days to weekly have been used in pediatric patients ≥2 years (Millia 1997; Scheinberg 2006). Maximum daily dose: 40 mg/day (Lubsch 2006). Note: To minimize dose-related side effects (eg, sedation), lower initial doses (eg, 2.5 mg once daily) and slower titration may be considered (eg, weekly) and has been reported in pediatric patients >2 years (Scheinberg 2006). 2 to 7 years: Limited data available: 20 to 40 mg daily divided every 8 hours; begin at low end of range (or even lower [2.5 to 10 mg daily] and titrate dose to patient response; titration intervals of every 3 days to weekly have been used in pediatric patients. Maximum daily dose: 60 mg/day (Lubsch 2006; Millia 1997; Scheinberg 2006). ≥8 years and Adolescents: Limited data available in children daily divided every 8 hours; begin at low end of range (or even lower [10 mg to 15 mg daily in 3 divided doses]) and titrate dose to patient response, titration intervals of every 3 days to weekly have been used (Millia 1997; Scheinberg 2006); some patients ≥12 years may require every 6 hour dosing; usual maximum daily dose range: 60 to 80 mg/day (Lubsch 2006; Millia 1977). Note: Higher maximum daily doses (up to 200 mg/day) have been described in some patients in a retrospective review, usually the higher doses were needed over time (Lubsch 2006). Intrathecal: Children ≥4 years and Adolescents: Screening dose: Refer to adult dosing. Note: A 25 mcg initial screening dose may be considered in very small pediatric patients. Dose titration following pump implant: After positive response to screening dose, a maintenance intrathecal infusion can be administered via an implanted intrathecal pump. Initial total daily dose via pump: Double the screening dose that gave a positive response and administer over 24 hours, unless efficacy of the bolus dose was maintained for >8 hours, then infuse a dose equivalent to the screening dose over 24 hours. Do not increase dose in first 24 hours (to allow steady state to be ac
Oral: Refer to adult dosing; use with caution. If benefits are not observed, withdraw the drug slowly.
Oral: There are no dosage adjustments provided in the manufacturer’s labeling. However, baclofen is primarily eliminated renally; use with caution; dosage reduction may be necessary. The following dosage adjustments have been recommended (Vlavonou 2014; renal function estimated using the Cockcroft-Gault formula): CrCl >80 mL/minute: No initial dosage adjustment necessary. CrCl 50 to 80 mL/minute: Initial: 5 mg every 12 hours CrCl 30 to CrCl ESRD on hemodialysis: Avoid use (based on case reports; Chen 1997; El-Husseini 2011; Lee 2013; Su 2009); if baclofen must be used, initiate at a low dose with careful monitoring for toxicity (Lee 2013). Baclofen is readily removed by hemodialysis, with a report of 79% removal in a 4 hour session (Roberts 2015). Intrathecal: There are no dosage adjustments provided in the manufacturer’s labeling. However, baclofen is primarily renally eliminated; use with caution; dosage reduction may be necessary.
Oral and intrathecal: There are no dosage adjustments provided in the manufacturer’s labeling.

Warnings & Precautions

Source: Lexicomp

CNS depression

May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).

Intrathecal mass

Cases (most from pharmacy compounded preparations) of intrathecal mass formation at the implanted catheter tip have been reported; patients may experience worsening or return of spasticity, pain, inadequate response to dose adjustments, and/or neurological deficit/dysfunction. Neurosurgical evaluation and/or an appropriate imaging study should be considered if a mass is suspected.

Urinary retention

May cause acute urinary retention (may be related to underlying disease); use with caution in patients with urinary obstruction. Disease-related concerns:

Autonomic dysreflexia

Use intrathecal baclofen with caution in patients with a history of autonomic dysreflexia; presence of nociceptive stimuli or abrupt baclofen withdrawal may cause an autonomic dysreflexic episode.

Gastrointestinal disorders

Use with caution in patients with peptic ulcer disease, decreased GI motility, and/or gastrointestinal obstructive disorders.

Psychiatric disease

Use with caution in patients with psychotic disorders, schizophrenia, or confusional states; may cause exacerbation of condition.

Renal impairment

Use with caution in patients with renal impairment; baclofen is eliminated primarily unchanged via the kidneys. Multiple cases describing neurotoxicity due to oral baclofen accumulation in adult patients with varying levels of renal impairment have been reported in the literature. In patients with renal impairment, initiation of oral baclofen at lower doses and/or extended intervals has been suggested (Aisen 1994; Chen 1997; Chou 2006; El-Husseini 2011; Peces 1998; Su 2009; Vlavonu 2014).

Respiratory disease

Use with caution in patients with respiratory disease.

Seizure disorder

Use with caution in patients with a history of seizure disorder; monitor regularly for loss of seizure control. Seizures have been reported with withdrawal from intrathecal baclofen as well as in patients maintained on therapeutic doses of intrathecal baclofen. Special populations:

Elderly

Use with caution in elderly patients; may be more sensitive to adverse CNS effects, especially at higher doses.

Pediatric

Intrathecal: Children should be of sufficient body mass to accommodate the implantable pump for chronic infusion. Concurrent drug therapy issues:

Drug-drug interactions

Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Other warnings/precautions:

Abrupt withdrawal

Abrupt withdrawal of intrathecal baclofen, regardless of the cause, has resulted in sequelae (hyperpyrexia, altered mental status, exaggerated rebound spasticity, and muscle rigidity, which, in rare cases, has advanced to rhabdomyolysis), multiple organ-system failure, and death. Prevention of abrupt discontinuation requires careful attention to programming and monitoring of infusion system, refill scheduling and procedures, and pump alarms. Advise patients and caregivers of the importance of keeping scheduled refill visits and educate them on the early symptoms of baclofen withdrawal. Give special attention to patients at apparent risk (eg, spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal baclofen). Consult the technical manual of the implantable infusion system for additional postimplant clinician and patient information. In most cases, symptoms of withdrawal (eg, return of baseline spasticity, hypotension, paresthesia, pruritus) appear within hours to a few days following interruption of therapy. Priapism may develop or recur if treatment with intrathecal baclofen is interrupted. Clinically, the advanced intrathecal baclofen withdrawal syndrome may resemble autonomic dysreflexia, infection (sepsis), malignant hyperthermia, neuroleptic-malignant syndrome, or other conditions associated with a hypermetabolic state or widespread rhabdomyolysis. Suggested treatment for intrathecal baclofen withdrawal is r

Appropriate use

Intrathecal: For use only in an FDA-approved implantable pump for intrathecal baclofen administration; health care providers should be experienced with chronic intrathecal infusion therapy and resuscitative equipment should be readily available. Ensure patient is infection-free and then evaluate patient’s response to bolus intrathecal injection (screening phase) prior to implanting pump. Monitor closely during the initial phase of pump use and when adjusting the dosing rate and/or the concentration in the reservoir. Educate patients and caregivers on proper home care of the pump and insertion site. Use extreme caution when filling an implantable pump; pumps should only be refilled through the reservoir refill septum. Inadvertent injection into the subcutaneous tissue can occur if the reservoir refill septum is not properly accessed. Some pumps are equipped with a catheter access port that allows direct access to the intrathecal catheter; direct injection into this catheter access port or inadvertent injection into the subcutaneous tissue may cause a life-threatening overdose. Except in overdose related emergencies, intrathecal baclofen should be reduced slowly if discontinuation is necessary.

Appropriate use

Oral: Efficacy of oral baclofen has not been established in patients with stroke, Parkinson disease, or cerebral palsy; therefore, use is not recommended. Not indicated for spasticity associated with rheumatic disorders. Use with caution when spasticity is utilized to sustain upright posture and balance in locomotion, or when spasticity is necessary to obtain increased function.

Overdose

Intrathecal use: Monitor closely for signs and symptoms of overdose which may appear suddenly or insidiously, especially during the initial screening and dose-titration phase of treatment, and during reintroduction of therapy after a period of interruption. Signs/symptoms of overdose may include drowsiness, dizziness, somnolence, hypothermia, respiratory depression, seizures, rostral progression of hypotonia and loss of consciousness progressing to coma. If overdose is suspected, patient should be evaluated immediately in a hospital setting and the pump reservoir emptied.

Pregnancy & Lactation

Pregnancy

FDA category C

Adverse events have been observed in animal reproduction studies. Withdrawal symptoms in the neonate were noted in a case report following the maternal use of oral baclofen 20 mg 4 times/day throughout pregnancy (Ratnayaka 2001). Plasma concentrations following administration of intrathecal baclofen are significantly less than those with oral doses; exposure to the fetus is expected to be limited (Morton 2009).

Lactation

Avoid

Baclofen is excreted in breast milk. Very small amounts were found in the breast milk of a woman 14 days postpartum after oral use. Following a single oral dose of baclofen 20 mg, the total amount of baclofen excreted in breast milk within 26 hours was 22 mcg (Eriksson 1981). Adverse events were not observed in a nursing infant following maternal use of intrathecal baclofen 200 mcg/day throughout pregnancy and while nursing (Morton 2009). Due to the potential for adverse events in the nursing in

Monitoring

Clinical pearlRegular electroencephalogram (EEG) in patients with epilepsy (loss of seizure control has been reported).

Chemistry & Properties

2D structure
FormulaC10H12ClNO2
Molecular weight213.66 g/mol
IUPAC name4-amino-3-(4-chlorophenyl)butanoic acid
CAS1134-47-0
PubChem CID2284
InChIKeyKPYSYYIEGFHWSV-UHFFFAOYSA-N
logP1.86 (XLogP -1.0)
Polar surface area63.32 Ų
H-bond acceptors / donors2 / 2
Drug-likeness (QED)0.80
Lipinski violations0
SMILESNCC(CC(=O)O)c1ccc(Cl)cc1

Biology & Pharmacokinetics

Pharmacokinetics

BBB penetrantNo (logBB -1.52)

Enzyme interactions

EnzymeRoleDetail
CYP1A2Substrate
CYP2C19Substrate
CYP2C9Substrate

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)MCT1 (Inhibitor)MRP1 (Inhibitor)MRP2 (Inhibitor)MRP3 (Inhibitor)OAT3 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)OATP1B3 (Inhibitor)OCT1 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)

Drug–drug interactions (52, DDInter)

Interacting drugSeverityManagement
Codeine major
Hydrocodone major
Morphine major
Morphine (liposomal) major
Aldesleukin moderate
Alimemazine moderate
Amyl Nitrite moderate
Azatadine moderate
Azelastine (nasal) moderate
Brimonidine (ophthalmic) moderate
Brimonidine (topical) moderate
Brompheniramine moderate
Carbinoxamine moderate
Cetirizine moderate
Chlorphenesin moderate
Chlorpheniramine moderate
Clemastine moderate
Clofedanol moderate
Cyclizine moderate
Cyproheptadine moderate
Dexbrompheniramine moderate
Dextromethorphan moderate
Diazoxide moderate
Difenoxin moderate
Diphenhydramine moderate
Diphenoxylate moderate
Doxepin moderate
Doxepin (topical) moderate
Doxylamine moderate
Dronabinol moderate
Ethanol moderate
Ifosfamide moderate
Levocetirizine moderate
Meclizine moderate
Mepyramine moderate
Methdilazine moderate
Metoclopramide moderate
Minoxidil moderate
Nabilone moderate
Olopatadine (nasal) moderate

Showing 40 of 52.

Registered Products (3)

BrandForm / strengthPackAgentCitizen (JOD)
Baclocalm Tablet 10 mg/1 mg 50 tab ORIENT DRUG STORE CO 3.110
Lioresal Tab Tablet 10 mg 50 tab The Jordan Drugstore Co 4.880
Baclocalm Tablet 25 mg/1 mg 50 tab ORIENT DRUG STORE CO 6.380